Across TCGA pan-cancer cohorts, GRXCR2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GRXCR2 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher GRXCR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GRXCR2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUSC, SKCM, and LGG are the cancer types where GRXCR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.081	0.818	<.001	12	view →
SKCM	DFS	Median	All	0.427	0.183	.007	10	view →
LGG	OS	Median	All	0.332	0.830	.009	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: GRXCR2 tumor-vs-normal RNA expression · all GRXCR2 data types